Janssen has a long and proud history of innovation. Harnessing our deep experience in pharmaceuticals, combined with Johnson & Johnson's broad ophthalmic footprint, we venture to help more people with retinal diseases see a better future. Our global research teams are on a mission to restore and preserve vision in patients with blinding retinal diseases by discovering and developing transformational therapies that have an unequivocal advantage over standard of care and to prevent, treat, or cure diseases with critical global unmet needs. Beginning with the eye, Janssen is investigating gene therapies across varied mechanisms of action, building the case for future applications to other parts of the body.

Our nearest-term focus is hard-to-treat IRDs for which there is no current treatment, including XLRP. Additionally, we are focused on becoming the leading provider of innovative solutions for treating and managing geographic atrophy through the development and commercialization of cutting-edge therapies that can preserve sight and enhance the quality of life of those affected by this disease.


For more information about Janssen Retina’s research and portfolio, click here